retatrutide for diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase New Drug Retatrutide Shows Benefits

Treating these conditions poses a high economic burden

It works by increasing the availability of certain neurotransmitters like dopamine, norepinephrine, and histamine, thereby improving alertness, attention, and vigilance

These gallstones can then obstruct the bile ducts, leading to inflammation or infection, possibly necessitating gallbladder removal

It helps regenerate active glutathione from its oxidised form inside the body, which is why so many formulations pair the two together rather than selling glutathione alone

Lindsey Guldenschuh is a pharmacist who shares information with her followers about GLP-1 drugs, as both an expert and someone on them